A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

NCT03730012 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

Interventions

DRUG: gilteritinib
DRUG: atezolizumab

Sponsor

Astellas Pharma Global Development, Inc.